Medical - - Jun 15,2017
In the coming years, auto-injectors are expected to offer vast opportunities to investors due to the rising demand in biologics development; pre-filled syringes segment expected to surge.
Auto-injectors are pen-like devices which are used to deliver a static dose of the drug to patients and are planned for self-administration. Since the past few years, auto-injectors are slowly becoming the gold-standard in the treatment of different indications like multiple sclerosis, anaphylaxis, rheumatoid arthritis and others.
As per a recent research report published by Market Research Reports Search Engine (MRRSE), the anaphylaxis segment is found to be the most attractive segment with an anticipated CAGR of 15% by 2026. At this pace, the concerned segment might acquire more than US$ 6,000 Million during the same stated period.
As an interesting fact, auto-injectors are economical since they reduce about 95% of the primary healthcare costs, as there is no requirement to attend hospitals and clinics for the administration of the injection by healthcare professionals. Moreover, auto-injectors offer inexpensive home medication and also decrease the time consumed at in-patient and out-patient care units.
Looking at the current trends, auto-injectors are known to present vast opportunities to the investors as a result of high demand in biologics development. Also, the overall revenues acquired from the pre-filled syringes segment is likely to grow during in the coming years due to the enhanced need for targeted and sustained drug delivery.
The active market regions for auto-injectors currently include North America, Latin America, Eastern Europe, Western Europe, Asia-Pacific Excl. Japan (APEJ), Japan and the Middle East and Africa (MEA). Furthermore, the active channels for the distribution of auto-injectors are hospitals, pharmacies, online pharmacies, retail pharmacies and drug stores. Some of the prominent market players from this sector enjoying significant exposure are Becton, Dickinson and Company, Pfizer, Inc., Sanofi, Mylan N.V., Bayer AG and Novartis AG.
For more information on this report visit- http://www.mrrse.com/auto-injectors-market-report